Last reviewed · How we verify
Placebo of intravenous L-citrulline
Placebo of intravenous L-citrulline is a Small molecule drug developed by Asklepion Pharmaceuticals, LLC. It is currently in Phase 3 development.
This is a placebo control (inert substance) used in clinical trials to compare against active intravenous L-citrulline treatment.
At a glance
| Generic name | Placebo of intravenous L-citrulline |
|---|---|
| Sponsor | Asklepion Pharmaceuticals, LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo serves as the control arm in phase 3 trials to establish the efficacy and safety of L-citrulline independent of non-specific effects. L-citrulline itself is a non-essential amino acid that acts as a nitric oxide precursor, enhancing endothelial function and vasodilation. The placebo arm allows researchers to isolate the true pharmacological benefit of L-citrulline from placebo response.
Approved indications
Common side effects
Key clinical trials
- A Study of Intravenous L-Citrulline in Patients Aged 6-21 Years Old With Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis (PHASE3)
- Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease (PHASE2)
- A Study Evaluating the Efficacy and Safety of IV L-Citrulline for the Prevention of Clinical Sequelae of Acute Lung Injury Induced by Cardiopulmonary Bypass in Pediatric Patients Undergoing Surgery for Congenital Heart Defects (PHASE3)
- L-citrulline for Prevention of Sequelae of Acute Lung Injury in Pediatrics Undergoing Cardiopulmonary Bypass for Heart Defects (PHASE3)
- Intravenous L-Citrulline Influence on the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (PHASE2)
- Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery : Revised Protocol (PHASE1, PHASE2)
- Effects of Oral Citrulline on Protein Metabolism in Patients With Intestinal Failure (Citrugrêle 2) (PHASE3)
- Citrulline in Severe Sepsis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo of intravenous L-citrulline CI brief — competitive landscape report
- Placebo of intravenous L-citrulline updates RSS · CI watch RSS
- Asklepion Pharmaceuticals, LLC portfolio CI